Johnson & Johnson's nipocalimab could become the first approved treatment for a blood disorder that can lead to the death of a foetus or newborn, if positive results i
Shares in Johnson & Johnson have come under pressure amid reports that an appeals court in the US has rejected the bankruptcy petition filed by a new company it formed
One of Johnson & Johnson's top clinical trial readouts for 2023 just generated results, which bode very well for the future prospects of multiple myeloma CAR-T Carvykti.
Johnson & Johnson has been cleared to continue a lawsuit filed last year against drug benefit programme SaveOnSP, which claims it defrauded a payment assistance programme for patients o
It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt.
